Compare AURA & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AURA | SOPH |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 330.4M |
| IPO Year | 2021 | 2021 |
| Metric | AURA | SOPH |
|---|---|---|
| Price | $6.04 | $4.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.20 | $7.00 |
| AVG Volume (30 Days) | ★ 190.9K | 88.8K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $73,297,000.00 |
| Revenue This Year | N/A | $18.32 |
| Revenue Next Year | N/A | $15.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.66 |
| 52 Week Low | $4.35 | $2.58 |
| 52 Week High | $8.60 | $5.30 |
| Indicator | AURA | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 48.80 |
| Support Level | $5.72 | $4.60 |
| Resistance Level | $6.15 | $4.84 |
| Average True Range (ATR) | 0.27 | 0.24 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 35.57 | 15.38 |
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.